SOX2 and medulloblastoma: In SHH medulloblastoma (MB), quiescent SOX2+ cells could cause relapse where high frequency of SOX2+ cells revealed an increase in therapy-resistant MPCs (e.g. cytarabine or vismodegib), a predictive signature of poor outcome in patients with SHH-medulloblastoma (Vanner et al., 2014).